We are Minomic

Developer of novel cancer diagnostics

We have developed MiCheck® Prostate for prostate cancer

Trials

A series of clinical trials have shown MiCheck® Prostate yields more accurate results than existing blood tests for aggressive prostate cancer.

Diagnosis

MiCheck® Prostate fills a major need in prostate cancer diagnostics to follow on a reported elevated PSA level. It allows better triage of patients by differentiating aggressive cancer from non-aggressive or no cancer before an invasive and expensive biopsy.

Validation

We have formed a partnership with Cirrus Dx (US) to offer MiCheck® Prostate as a Laboratory Developed Test available through the Clinical Laboratory Improvements Amendment (CLIA) Act.

Distribution

We have partnered with Cirrus Dx to offer MiCheck® Prostate as a Laboratory Developed Test in your area.

 

Company Pipeline Development Summary

Minomic Pipeline

Company Background

We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Our reach is global, through partnerships with universities, research institutes, and companies.

Our experience is backed up by independent experts in oncology, awards of multiple research grants, a major innovation prize, and investment backing of over A$27 million to date.

Extensive intellectual property

Minomic owns an extensive patent estate protecting our distinctive technology. All the intellectual property relevant to our technology is owned by us.

Our investors and funding support

Minomic is an unlisted public company.

Apart from equity investment, other sources of funding 
include:

Contact us if you are interested in investing in the future of Minomic International.

Privacy Policy